Literature DB >> 29755128

Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma.

David J Pinato1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29755128     DOI： 10.1038/s41388-018-0262-8

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


× No keyword cloud information.
  25 in total

1.  Recurrence of hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

Review 2.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 3.  Molecular monitoring of chronic myeloid leukemia: present and future.

Authors:  Cecilia Ching Sze Yeung; Daniel Egan; Jerald P Radich
Journal:  Expert Rev Mol Diagn       Date:  2016-09-06       Impact factor: 5.225

4.  Circulating free DNA in the progression of liver damage to hepatocellular carcinoma.

Authors:  Marika Piciocchi; Romilda Cardin; Alessandro Vitale; Veronica Vanin; Anna Giacomin; Caterina Pozzan; Gemma Maddalo; Umberto Cillo; Maria Guido; Fabio Farinati
Journal:  Hepatol Int       Date:  2013-11-02       Impact factor: 6.047

5.  Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Authors:  Alexander Gerbes; Fabien Zoulim; Herbert Tilg; Jean-François Dufour; Jordi Bruix; Valérie Paradis; Riad Salem; Markus Peck-Radosavljevic; Peter R Galle; Tim F Greten; Jean-Charles Nault; Matias A Avila
Journal:  Gut       Date:  2017-11-17       Impact factor: 23.059

6.  Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Authors:  Sadakatsu Ikeda; Jordan S Lim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

7.  Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Authors:  Yulian Khagi; Aaron M Goodman; Gregory A Daniels; Sandip P Patel; Assuntina G Sacco; James M Randall; Lyudmila A Bazhenova; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-10-01       Impact factor: 12.531

Review 8.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

9.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

10.  Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma.

Authors:  Venkatesh Kancherla; Samir Abdullazade; Matthias S Matter; Manuela Lanzafame; Luca Quagliata; Guglielmo Roma; Yujin Hoshida; Luigi M Terracciano; Charlotte K Y Ng; Salvatore Piscuoglio
Journal:  Front Genet       Date:  2018-02-02       Impact factor: 4.599
View more
  1 in total

1.  Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.

Authors:  Gui-Qi Zhu; Wei-Ren Liu; Zheng Tang; Wei-Feng Qu; Yuan Fang; Xi-Fei Jiang; Shu-Shu Song; Han Wang; Chen-Yang Tao; Pei-Yun Zhou; Run Huang; Jun Gao; Hai-Xiang Sun; Zhen-Bin Ding; Yuan-Fei Peng; Zhi Dai; Jian Zhou; Jia Fan; Ying-Hong Shi
Journal:  Mol Oncol       Date:  2021-10-04       Impact factor: 6.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.